Upon joining the study, you will be required to sign an informed consent form. This form confirms your understanding of the study and your willingness to participate.

If you are between 16 and 18 years old, you may also need to sign an assent form, depending on local guidelines.

An initial assessment will be conducted to confirm your diagnosis of moderately to severely active Crohn’s disease. This includes reviewing your medical history and conducting necessary tests.

Your body weight will be measured to ensure it is at least 40 kg, as this is a requirement for participation.

A baseline evaluation will be performed to assess the current state of your Crohn’s disease. This involves measuring the Crohn’s Disease Activity Index (CDAI) and the Simple Endoscopic Score for Crohn’s Disease (SES-CD).

The CDAI score should be between 220 and 450, and the SES-CD should be at least 6, or 4 for isolated ileal disease.

During the treatment phase, you will receive either the study medication RO7790121 or a placebo. This is a double-blind study, meaning neither you nor the study team will know which treatment you are receiving.

The medication will be administered according to the study protocol, which will be explained to you in detail by the study team.

You will undergo regular monitoring to assess the effectiveness and safety of the treatment. This includes clinical evaluations and endoscopic assessments.

Your symptoms and any side effects will be closely monitored throughout the study.

At the end of the study, a final evaluation will be conducted to determine the overall response to the treatment.

The primary goals are to achieve clinical remission and an endoscopic response, which will be measured by improvements in your CDAI and SES-CD scores.